EASD Highlights

In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) kindly shared her highlights from this year’s EASD 2022. Questions: What in your opinion are the key highlights of this year’s EASD congress? (0:20) How do you think some of these highlights may impact clinical practice? (2:15) What do you think are […]

Insulin icodec is a novel, long-acting insulin analog designed for once-weekly administration that is in development for the treatment of diabetes. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital […]

Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior to either agent alone. In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School […]

There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School of Medicine, Durham, NC, USA) discusses the unmet needs in reducing the risk of CKD […]

Diabetic foot ulcer is a complication of diabetes with a yearly incidence around 2–4%. Ulcer healing can take weeks or months, with one-third of ulcers never healing.1 In this touchENDOCRINOLOGY interview, Dr Ashu Rastogi (Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India) discusses the goals of diabetic foot treatment as well as […]

In this touchENDOCRINOLOGY interview, Dr Ashu Rastogi (Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India) discusses the first randomized, double-blind, placebo-controlled, parallel-group, multi-centre, phase III study evaluating the efficacy of topical esmolol for diabetic foot ulcer healing. Dr Ashu Rastogi also discusses how these results support physicians in providing optimized care for […]

Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]

The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]

Diabetes increases the risk of cardiovascular (CV) and renal disease (CVRD). These become major causes of mortality in individuals with diabetes. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses the relationship between cardiovascular and renal risks in diabetes The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants […]